Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
<p><strong>Background:</strong> Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help con...
| Príomhchruthaitheoirí: | , , , , , , |
|---|---|
| Formáid: | Journal article |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
American Society of Nephrology
2022
|